iScience (Jan 2024)

SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model

  • Sarah E. Cummings,
  • Sean P. Delaney,
  • Frederic St-Denis Bissonnette,
  • Andrew Stalker,
  • Gauri Muradia,
  • Jelica Mehic,
  • Tyson E. Graber,
  • Tommy Alain,
  • Jessie R. Lavoie

Journal volume & issue
Vol. 27, no. 1
p. 108708

Abstract

Read online

Summary: Extracellular vesicles (EVs) are entering the clinical arena as novel biologics for infectious diseases, potentially serving as the immunogenic components of next generation vaccines. However, relevant human assays to evaluate the immunogenicity of EVs carrying viral antigens are lacking, contributing to challenges in translating rodent studies to human clinical trials. Here, we engineered EVs to carry SARS-CoV-2 Spike to evaluate the immunogenicity of antigen-carrying EVs using human peripheral blood mononuclear cells (PBMCs). Delivery of Spike EVs to PBMCs resulted in specific immune cell activation as assessed through T cell activation marker expression. Further, Spike EVs were taken up largely by antigen-presenting cells (monocytes, dendritic cells and B cells). Taken together, this human PBMC-based system models physiologically relevant pathways of antigen delivery, uptake and presentation. In summary, the current study highlights the suitability of using human PBMCs for evaluating the immunogenicity of EVs engineered to carry antigens for infectious disease therapeutics.

Keywords